Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases
暂无分享,去创建一个
M. Fiegl | A. Tzankov | G. Mikuz | W. Hilbe | W. Sterlacci | J. Auberger
[1] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.
[2] M. D. Di Marino,et al. Neuroendocrine differentiation in non-small cell lung carcinomas. , 2000, In vivo.
[3] G. Pelosi,et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma , 2003, Cancer.
[4] Jacques Ferlay,et al. Cancer incidence in five continents. , 1976, IARC scientific publications.
[5] S. Cha,et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy‐treated nonsmall cell lung carcinoma , 1996, Cancer.
[6] R. Wood‐Baker,et al. Nonsmall Cell Lung Carcinoma With Neuroendocrine Differentiation—An Entity of No Clinical or Prognostic Significance , 2007, The American journal of surgical pathology.
[7] Y. Haga,et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. , 2002, The Annals of thoracic surgery.
[8] Elisabeth Brambilla,et al. Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .
[9] Farin Kamangar,et al. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Kerr,et al. Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy , 2005, Histopathology.
[11] Armando Santoro,et al. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] L. Fabbri,et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Baskić,et al. Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. , 2008, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[14] R. Greil,et al. [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]. , 2007, Wiener klinische Wochenschrift.
[15] A. Gajra,et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. , 2002, Lung cancer.
[16] J. Carles,et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. , 1993, Lung cancer.
[17] S. Takashima,et al. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications , 2009, Journal of Cancer Research and Clinical Oncology.
[18] Martin W. Bunder,et al. The inconsistency of , 1976, Journal of Symbolic Logic.
[19] L. Fabbri,et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung , 2005 .
[20] S. Störkel,et al. Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[21] N. Perkins,et al. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. , 2006, American journal of epidemiology.
[22] A. Marchevsky,et al. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. , 2001, American journal of clinical pathology.
[23] F. Levi,et al. Cancer incidence in five continents, vol. VI , 1993 .
[24] Alexandar Tzankov,et al. Tissue microarray technology: principles, pitfalls and perspectives—lessons learned from hematological malignancies , 2005, Experimental Gerontology.
[25] R. Greil,et al. Twelve-year retrospective analysis of lung cancer--The TYROL Study: Daily routine in 1,424 patients (1995-2006) , 2008 .
[26] Kenji Suzuki,et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. , 2002, The Journal of thoracic and cardiovascular surgery.
[27] F. Ploner,et al. Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom , 2007, Wiener klinische Wochenschrift.
[28] J. Mortimer,et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.